Gadens and BioMelbourne Network hosted a webinar on Wednesday, 17 November 2021 to discuss the new laws, duties, stakeholders and risks directors need to navigate after their company conducts an IPO.
Gadens Corporate Partner Matt Egerton-Warburton guided participants through the major issues and governance challenges that arise as a company transitions from a privately held entity to a listed organisation.
Matt was joined by Grant Chamberlain (Partner at OneVentures and Non-Executive Director of ASX and Nasdaq listed Immutep Ltd) and Melanie Farris (Chief Governance and Risk Officer and Group Company Secretary at ASX listed Telix Pharmaceuticals) who provided their perspectives and experiences.
Watch the full session below, chaired by Jeff Malone, CEO of BioMelbourne Network.
Recorded on Wednesday, 17 November 2021.
Matt Egerton-Warburton, Partner